Transposition and implementation of EU rare disease policy in Eastern Europe [0.03%]
东欧的欧盟罕见病政策的转化和实施
Ana V Pejcic,Georgi Iskrov,Ralitsa Raycheva et al.
Ana V Pejcic et al.
А series of European Union (EU) political decisions have made rare diseases one of the cornerstones of the common European health policy. Adopted in 2009, Council Recommendation on an action in the field of rare diseases aimed to serve as ...
Reviewing back translation reports of questionnaires: the EORTC conceptual framework and experience [0.03%]
回顾问卷的逆向翻译报告：EORTC 的理论框架与经验
Dagmara Kuliś,Cheryl Whittaker,Eva Greimel et al.
Dagmara Kuliś et al.
In the process of translating patient-reported outcomes measures (forward translation(s), reconciliation, back translation(s), review, pilot-testing, review, final translation), there is a general consensus amongst the key players in the fi...
Healthcare costs and quality of life outcomes following gender affirming surgery in trans men: a review [0.03%]
男性跨性别者的性别确认手术后的医疗费用和生活质量结局：综述
Justine Defreyne,Joz Motmans,Guy T&#x;sjoen
Justine Defreyne
Options for gender affirming therapy in trans men include social transitioning, mental coaching, hormonal therapy and gender affirming surgery. Research has concluded that gender affirming therapy is safe and feasible and generally leads to...
Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer [0.03%]
帕博珠单抗联合曲妥珠单抗和多西他赛作为HER-2阳性转移性乳腺癌一线治疗的疗效成本分析
Henry W C Leung,Agnes L F Chan,Chih-Hsin Muo et al.
Henry W C Leung et al.
Objective: To provide perspective for the National Health Insurance Bureau (NHIB), we determined the cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel (TDP) versus trastuzumab and docetaxel (TD) as ...
Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015 [0.03%]
波兰2013至2015年医保报销决策趋势及影响因素分析
Paweł Kawalec,Krzysztof Piotr Malinowski,Wojciech Trąbka
Paweł Kawalec
Objective: To assess changes in the involvement of advisory bodies in the reimbursement decision-making process in Poland, and to evaluate variables that influenced HTA recommendations in the years 2013-2015. ...
Ann M Moyer,Pedro J Caraballo
Ann M Moyer
Pharmacogenomic testing has the potential to greatly benefit patients by enabling personalization of medication management, ensuring better efficacy and decreasing the risk of side effects. However, to fully realize the potential of pharmac...
The value of innovation in decision-making in health care in Central Eastern Europe - The Sixth International Conference, 2 June 2017, Belgrade, Serbia [0.03%]
医疗卫生决策中的创新价值——医疗保健创新决策第六国际会议，2017年6月2日，塞尔维亚贝尔格莱德
Tanja Novakovic,Antony P Martin,Mark Parker et al.
Tanja Novakovic et al.
The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia organised a one day international conference on the value of innovation in decision-making in health care in Central and Eastern Europe. The focus of the conference w...
Applying stated-preference methods to improve health systems in sub-Saharan Africa: a systematic review [0.03%]
应用于非洲撒哈拉以南地区卫生系统的声明偏好法的系统性综述
Lauren Brown,Ting-Hsuan Lee,Manuela De Allegri et al.
Lauren Brown et al.
Sub-Saharan African health systems must balance shifting disease burdens with desires for robust institutions. Stated-preference methods have been applied extensively to elicit health care workers' preferences and priorities for rural pract...
Athanasios Dellis,Athanasios Papatsoris
Athanasios Dellis
Recently, LHRH antagonists have been established in the management of advanced prostate cancer, although the vast majority of Medical Oncologists and Urologists still prefer the LHRH agonists. Areas Covered: In this article we assess the th...
Best-worst scaling to assess the most important barriers and facilitators for the use of health technology assessment in Austria [0.03%]
最佳-最差尺度评估奥地利卫生技术评估应用最重要的障碍和促进因素
Chiara Feig,Kei Long Cheung,Mickaël Hiligsmann et al.
Chiara Feig et al.
Background: Although Health Technology Assessment (HTA) is increasingly used to support evidence-based decision-making in health care, several barriers and facilitators for the use of HTA have been identified. This best-w...